Tejas Savant
Stock Analyst at Morgan Stanley
(2.19)
# 2,713
Out of 4,884 analysts
235
Total ratings
40.29%
Success rate
-4.95%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $9 → $7 | $3.61 | +93.91% | 9 | May 28, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $26 → $18 | $13.01 | +38.36% | 14 | May 19, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $136 → $100 | $100.34 | -0.34% | 8 | May 12, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $60 → $65 | $59.18 | +9.83% | 3 | May 9, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $77 → $65 | $65.30 | -0.46% | 9 | May 5, 2025 | |
| CYRX Cryoport | Maintains: Equal-Weight | $8 → $7 | $7.46 | -6.17% | 2 | May 5, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $7 → $9 | $11.48 | -21.60% | 12 | May 5, 2025 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $17 → $10 | $7.40 | +35.14% | 13 | May 1, 2025 | |
| AVTR Avantor | Downgrades: Equal-Weight | $25 → $15 | $13.89 | +7.99% | 17 | Apr 28, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Equal-Weight | $7 → $5 | $2.65 | +88.68% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $47.56 | -57.95% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $176 → $185 | $161.57 | +14.50% | 13 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $245 → $250 | $164.65 | +51.84% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $647 → $678 | $427.76 | +58.50% | 14 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $24.48 | -6.05% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $27.58 | +1.52% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $5.64 | +272.67% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.49 | +34.23% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $3 | $1.37 | +118.98% | 10 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $12.66 | +215.96% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $0.78 | +666.28% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $3.05 | +227.87% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.52 | -21.88% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $7.51 | -33.38% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.21 | +352.49% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $50.18 | +45.48% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $157.49 | +58.74% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.28 | +1,718.18% | 5 | May 12, 2022 |
Cytek Biosciences
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $3.61
Upside: +93.91%
10x Genomics
May 19, 2025
Maintains: Overweight
Price Target: $26 → $18
Current: $13.01
Upside: +38.36%
Illumina
May 12, 2025
Maintains: Equal-Weight
Price Target: $136 → $100
Current: $100.34
Upside: -0.34%
Tempus AI
May 9, 2025
Maintains: Overweight
Price Target: $60 → $65
Current: $59.18
Upside: +9.83%
Hologic
May 5, 2025
Maintains: Equal-Weight
Price Target: $77 → $65
Current: $65.30
Upside: -0.46%
Cryoport
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $7.46
Upside: -6.17%
Adaptive Biotechnologies
May 5, 2025
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $11.48
Upside: -21.60%
NeoGenomics
May 1, 2025
Maintains: Equal-Weight
Price Target: $17 → $10
Current: $7.40
Upside: +35.14%
Avantor
Apr 28, 2025
Downgrades: Equal-Weight
Price Target: $25 → $15
Current: $13.89
Upside: +7.99%
Maravai LifeSciences Holdings
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.65
Upside: +88.68%
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $47.56
Upside: -57.95%
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $161.57
Upside: +14.50%
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $164.65
Upside: +51.84%
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $427.76
Upside: +58.50%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $24.48
Upside: -6.05%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $27.58
Upside: +1.52%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $5.64
Upside: +272.67%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.49
Upside: +34.23%
Aug 6, 2024
Downgrades: Equal-Weight
Price Target: $4 → $3
Current: $1.37
Upside: +118.98%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $12.66
Upside: +215.96%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $0.78
Upside: +666.28%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $3.05
Upside: +227.87%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.52
Upside: -21.88%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $7.51
Upside: -33.38%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.21
Upside: +352.49%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $50.18
Upside: +45.48%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $157.49
Upside: +58.74%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.28
Upside: +1,718.18%